Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 338

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 338
---
 stock in connection with equity award plans337,963— 1,205 — — 1,205 Stock-based compensation—— 11,664 — — 11,664 Net loss—— — (25,279)— (25,279)Other comprehensive loss—— — — (1,657)(1,657)Balance as of March 31, 202447,061,1065 816,129 (581,518)(13)234,603 Issuance of common stock in connection with equity award plans442,652— 5,858 — — 5,858 Issuance of common stock in connection with employee stock purchase plan68,089— 1,433 — — 1,433 Stock-based compensation—— 12,196 — — 12,196 Net loss—— — (24,638)— (24,638)Other comprehensive loss—— — — (464)(464)Balance as of June 30, 202447,571,847$5 $835,616 $(606,156)$(477)$228,988 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 Six Months Ended June 30, 20252024Operating activitiesNet loss$(20,538)$(49,917)Reconciliation of net loss to net cash provided by operating activities:Stock-based compensation34,271 23,285 Depreciation and amortization12,108 11,518 Inventory reserves and firm commitment losses2,349 1,676 Amortization of debt discount and offering costs860 821 Unrealized foreign exchange gain(1,270)(2,089)Non-cash lease expense826 585 Other(674)25 Change in operating assets and liabilities:Accounts receivable(25,901)7,538 Prepaid and other current assets(7,114)2,345 Inventory(5,007)(2,049)Other assets(1,342)(88)Accounts payable, accrued expenses and other liabilities22,314 18,221 Operating lease liabilities(803)(462)Net cash provided by operating activities10,079 11,409 Investing activitiesPurchase of investments(65,